Oral Levosimendan Increases Cerebral Blood Flow Velocities in Patients with a History of Stroke or Transient Ischemic Attack: A Pilot Safety Study

Current Therapeutic Research - Clinical and Experimental

Volumn 77, Issue , 2015, Pages 46-51

  Kivikko, Matti ^a,b   Kuoppamäki, Mikko ^b   Soinne, Lauri ^a   Sundberg, Stig ^c   Pohjanjousi, Pasi ^b   Ellmen, Juha ^b   Roine, Risto O ^d  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b ORION CORPORATION   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Ambulatory ECG; Cerebral blood flow; Levosimendan; Stroke; TIA

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; DIPYRIDAMOLE; LEVOSIMENDAN; PLACEBO;

ADULT; AGED; APNEA; ARTICLE; BACKACHE; BLOOD FLOW VELOCITY; BRAIN BLOOD FLOW; BREATH HOLDING; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DOPPLER ECHOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; GASTROENTERITIS; HEADACHE; HEART RATE; HEART VENTRICLE TACHYCARDIA; HUMAN; MALE; MEDICAL HISTORY; MULTICENTER STUDY; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SEPSIS; SINUS TACHYCARDIA; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK;

EID: 84925372636     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2015.01.001     Document Type: Article

References (25)

1. Papp Z., Edes I., Fruhwald S., De Hert S.G., et al. Levosimendan: Molecular mechanisms and clinical implications. Consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 2012, 23(159):82-87.
2. Nieminen M.S., Akkila J., Hasenfuss G., et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000, 36:1903-1912.
3. Packer M., Colucci W., Fisher L., et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013, 1:103-111. REVIVE Heart Failure Study Group.
4. Slawsky M.T., Colucci W.S., Gottlieb S.S., et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000, 102:2222-2227.
5. Mebazaa A., Nieminen M.S., Packer M., et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007, 297:1883-1891.
6. Levijoki J., Kivikko M., Pollesello P., et al. Levosimendan alone and in combination with valsartan prevents stroke in Dahl salt-sensitive rats. Eur J Pharmacol 2015, [in press].
7. Hein M., Zoremba N., Bleilevens C., et al. Levosimendan limits reperfusion injury in a rat middle cerebral artery occlusion (MCAO) model. BMC Neurol 2013, 13:106.
8. Kersten J.R., Montgomery M.W., Pagel P.S., Warltier D.C. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of KATP channels. Anesth Analg 2000, 90:5-11.
9. Parissis J.T., Karavidas A., Bistola V., et al. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis 2008, 197:278-282.
10. Kaptan K., Erinç K., Ifran A., et al. Levosimendan has anti-inhibitory effect on platelet function. Am J Hematol 2008, 83:46-49.
11. Nieminen M.S., Cleland J.G., Eha J., et al. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study. Eur J Heart Fail 2008, 10:1246-1254.
12. Silvestrini M., Vernieri F., Pasqualetti P., et al. Impaired cerebral vasoreactivity and risk of stroke in patients with asymptomatic carotid artery stenosis. JAMA 2000, 283:2122-2127.
13. Puttonen J., Laine T., Ramela M., et al. Pharmacokinetics and excretion balance of OR-1896, a pharmacologically active metabolite of levosimendan, in healthy men. Eur J Pharm Sci 2007, 32:271-277.
14. Põder P., Eha J., Sundberg S., et al. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study. J Clin Pharmacol 2004, 44:1143-1150.
15. Bravo MdC López P, Cabañas F., et al. Acute Effects of Levosimendan on Cerebral and Systemic Perfusion and Oxygenation in Newborns: An Observational Study. Neonatology 2011, 99:217-223.
16. Cengiz S.L., Erdi M.F., Tosun M., et al. Beneficial effects of levosimendan on cerebral vasospasm induced by subarachnoid haemorrhage: An experimental study. Brain Injury 2010, 24:877-885.
17. Qian Y., Bi Q. Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. Eur J Med Res 2013, 18:53.
18. de Sousa M.R., Morillo C.A., Rabelo F.T., et al. Non-sustained ventricular tachycardia as a predictor of sudden cardiac death in patients with left ventricular dysfunction: A meta-analysis. Eur J Heart Fail 2008, 10:1007-1014.
19. Hedblad B., Janzon L., Johansson B.W., Juul-Moller S. Survival and incidence of myocardial infarction in men with ambulatory ECG-detected frequent and complex ventricular arrhythmias. 10 year follow-up of the 'Men born 1914' study in Malmo, Sweden. Eur Heart J 1997, 18:1787-1795.
20. Agarwal S.K., Heiss G., Rautaharju P.M., et al. Premature ventricular complexes and risk of incident stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Stroke 2010, 41:588-593.
21. Toivonen L., Viitasalo M., Sundberg S., et al. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol 2000, 35:664-669.
22. Stolker J.M., Rich M.W. Clinical utility of B-type natriuretic peptide for estimating left ventricular filling pressures in unselected elderly patients undergoing diagnostic coronary angiography. J Invasive Cardiol 2010, 22:107-112.
23. Hays A.G., Sacco R.L., Rundek T., et al. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke 2006, 37:1715-1719.
24. Kivikko M., Antila S., Eha J., et al. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002, 40:465-471.
25. Antila S., Pesonen U., Lehtonen L., et al. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci 2004, 23:213-222.